Login to Access Video or Poster Abstract: MP40-19
Sources of Funding: none_x000D_

Introduction

The aims of this study were to evaluate the medication adherence, the patient’s satisfaction and the improvement of symptoms and _x000D_ of quality of life in women with OAB after treatment with Mirabegron._x000D_

Methods

This is an multicenter prospective study.Consecutive female patients affected by OAB were enrolled. Inclusion criteria were: women with OAB naïve, women with refractory OAB to antimuscarinic drugs. Exclusion criteria were:hypertension, renal and hepatic impairment, QT prolongation. Pre-treatment evaluation: microbiological analysis, abdominal ultrasonography, uroflowmetry (UF) with post-void residual (PVR) measurement and voiding diary (VD). They completed OABq- sf questionnaire. They received once-daily Mirabegron 50 mg for 6 months.They were followed up at 1,3,6 months post treatment with UF and PVR measurement and 3-days VD, OABq-sf, MMAS-4 sf, sVAS and PGI-I questionnaries. Statistical analysis : McNemar and Friedman tests, p-value <0.05

Results

Ninety-two women (mean age of 56.4±13.4 years) were included in the study. 23 and 33 patients interrupted the treatment at 1 and 3 months respectively. Graph I (A,B) showed the discontinuation reasons. 36 out of 92 women were evaluated at 6 months with a high drug adherence (median MMAS-4 score of 0 (range 0-2) ). At 6 months follow-up patient’s satisfaction was high, infact median PGI-I and S-VAS were 2 (range 1-4) and 8 (2-10) respectively. At 1,3,6 months OABq-sf score showed a statistically significant improvement with a baseline median score of 36 (range 19-99), of 9 (range 7-24) at 6 months (p=0.001). Graph 1C showed an improvement of all the OAB symptoms at 1 and 3 months, but they were stable at 6 months. Furthermore a statistically significant decrement of the mean number of pads/die was evident at 6 month (1.45±1.58 vs 0.57 ± 0.98 p<0.0001).UF results showed no statistical changes at 1 month and at 6 months.The results are not different in women with OAB naïve and women with OAB refractory to antimuscarinic drugs

Conclusions

Mirabegron 50mg showed significant subjective and objective efficacy with a high in women with OAB at 1 and 3 months of treatment. For the low side-effects and its impact on QoL, it can be considered the first line therapy in these patients. Long term results are mandatory for patients perspective and counselling for tailored therapy._x000D_ _x000D_ _x000D_

Funding

none_x000D_